Home/ Stocks/ CCCC

C4 Therapeutics, Inc.

CCCC XNAS

$3.73 +0.09 (+2.47%) ▲ 15-min delayed

Open

$3.69

High

$3.75

Low

$3.65

Volume

1.47M

Market Cap

$402.46M

About C4 Therapeutics, Inc.

C4 Therapeutics Inc is a clinical-stage biopharmaceutical company dedicated to delivering on the promise of targeted protein degradation science to create a new generation of medicines that transforms patient's lives. The Company is progressing targeted oncology programs through clinical studies and leveraging its TORPEDO platform to efficiently design and optimize small-molecule medicines to address difficult-to-treat diseases. The degrader medicines of the company are designed to harness the body's natural protein recycling system to rapidly degrade disease-causing proteins, offering the potential to overcome drug resistance, and drug undruggable targets and improve patient outcomes. Its pipeline is Cemsidomide, CFT8919, and other discovery products.

Sector: BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES) Employees: 104 Website →

Key Financials

Period	Revenue	Net Income	EPS
Q1 2026	$6.15M	$-25,129,000	$-0.20
FY 2025	$35.95M	$-104,994,000	$-1.27
Q3 2025	$11.23M	$-32,166,000	$-0.44
Q2 2025	$6.46M	$-26,020,000	$-0.37

Earnings & Analyst Ratings

Next Earnings: Wed, Nov 4, 2026

Calendar →

Related Market News

No specific coverage for CCCC yet. Check out our latest market news or earnings calendar.

Get CCCC Alerts

Stay ahead with breaking news, price alerts, and expert analysis on C4 Therapeutics, Inc..

Disclaimer: This page is for informational purposes only. Stock data is delayed by at least 15 minutes. Always conduct your own research and consult with a qualified financial advisor before making investment decisions.